Small intestinal bacterial growth (SIBO) is commonly seen in the presence of one or more predisposing conditions. It varies highly based on the underlying disorders and microbiota characteristics of patients and organisms. SIBO results in gastrointestinal IBS-like symptoms, which could be asymptomatic. In worse cases, it may result in real malabsorption syndrome. The presence of SIBO is generally diagnosed with hydrogen lactulose and glucose breath tests. These tests are widely performed in every clinical setting due to their low costs, non-invasively, sufficient accuracy, and reproducibility.
The most notable market participants are Genova Diagnostics, SIBO Diagnostics, Commonwealth Diagnostics International, Aerodiagnostics, LLC, SIBOTest, Metabolic Solutions, Inc., Pivotal Diagnostics, DirectLabs, LLC, Vibrant Wellness, and Health Associates Medical Group among others, occupying a considerable share of the market owing to their offerings to the market.
Aerodiagnostics, LLC, and Genova Diagnostics – Notable Market Participants in Small Intestinal Bacterial Overgrowth Diagnostics Market
Market players are involved in offering the services that contribute to quality enhancement for services and cost efficiency within healthcare services. For instance, in September 2020, Genova Diagnostics has partnered with Rocky Mountain Analytical, a subsidiary of LifeLabs, a leading provider of naturopathic and functional medicine. This partnership allows greater accessibility and cost effectiveness of Genova Diagnostics testing for Canadian clinicians and patients.
Prominent players in SIBO diagnostics market are focusing on majorly on organic strategies such as product launch to garner their significance and remain competitive in the market. Few of the important key developments from the industry are mentioned below:
|
Year |
News |
|
Feb-2020 |
Commonwealth Diagnostics International (CDI), Inc., announced the commercial re-launch of IBSchek, the first clinically validated biomarker blood test for diarrhea-predominant and mixed-type Irritable Bowel Syndrome (IBS-D, IBS-M) in a new at-home capillary collection kit. |
|
Feb-2021 |
The American Medical Association (AMA) has granted Commonwealth Diagnostics International, Inc.’s IBSchek a PLA code; the company will now accept insurance, allowing more patients at-home access. Commonwealth Diagnostics International, Inc. (CDI) will begin accepting insurance immediately for their proprietary IBSchek Capillary Collection Kit. Clinically validated in 2015 and revalidated internationally, IBSchek is the most reliable diagnostic blood test for both diarrhea-predominant and mixed-symptom IBS (IBS-D/M) in the market. |
|
Sep-2018 |
Vibrant Wellness has launched IBSSure diagnostic platform for SIBO detection. Vibrant IBSSure is a tool to determine IgG antibodies to antigens – Vinculin and Cytolethal Distending Toxin B (CdtB) tested using a chemiluminescent technology delivering high sensitivity and specificity of detection. |
